Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer.

van Rooijen JM, Qiu SQ, Timmer-Bosscha H, van der Vegt B, Boers JE, Schröder CP, de Vries EGE.

Eur J Cancer. 2018 Nov;103:52-60. doi: 10.1016/j.ejca.2018.08.001. Epub 2018 Sep 9.

PMID:
30208359
2.

Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma.

Kruizinga RC, van Marion DM, den Dunnen WF, de Groot JC, Hoving EW, Oosting SF, Timmer-Bosscha H, Derks RP, Cornelissen C, van der Luijt RB, Links TP, de Vries EG, Walenkamp AM.

Fam Cancer. 2016 Oct;15(4):607-16. doi: 10.1007/s10689-016-9879-3.

3.

Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection.

Tjalma JJ, Garcia-Allende PB, Hartmans E, Terwisscha van Scheltinga AG, Boersma-van Ek W, Glatz J, Koch M, van Herwaarden YJ, Bisseling TM, Nagtegaal ID, Timmer-Bosscha H, Koornstra JJ, Karrenbeld A, Kleibeuker JH, van Dam GM, Ntziachristos V, Nagengast WB.

J Nucl Med. 2016 Mar;57(3):480-5. doi: 10.2967/jnumed.115.166975. Epub 2015 Dec 17.

4.

Studying cancer metastasis: Existing models, challenges and future perspectives.

van Marion DM, Domanska UM, Timmer-Bosscha H, Walenkamp AM.

Crit Rev Oncol Hematol. 2016 Jan;97:107-17. doi: 10.1016/j.critrevonc.2015.08.009. Epub 2015 Aug 10. Review.

PMID:
26321372
5.

Human stromal cells are required for an anti-breast cancer effect of zoledronic acid.

Nienhuis HH, Arjaans M, Timmer-Bosscha H, de Vries EG, Schröder CP.

Oncotarget. 2015 Sep 15;6(27):24436-47.

6.

Hormone receptors as a marker of poor survival in epithelial ovarian cancer.

van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hospers G, Reyners A.

Gynecol Oncol. 2015 Sep;138(3):634-9. doi: 10.1016/j.ygyno.2015.06.032. Epub 2015 Jun 24.

PMID:
26115976
7.

Microenvironment involved in FPR1 expression by human glioblastomas.

Boer JC, van Marion DM, Joseph JV, Kliphuis NM, Timmer-Bosscha H, van Strijp JA, de Vries EG, den Dunnen WF, Kruyt FA, Walenkamp AM.

J Neurooncol. 2015 May;123(1):53-63. doi: 10.1007/s11060-015-1777-2. Epub 2015 Apr 19.

8.

CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment.

Tamas K, Domanska UM, van Dijk TH, Timmer-Bosscha H, Havenga K, Karrenbeld A, Sluiter WJ, Beukema JC, van Vugt MA, de Vries EG, Hospers GA, Walenkamp AM.

Curr Pharm Des. 2015;21(17):2276-83.

PMID:
25557636
9.

Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.

Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schröder CP.

Pharmacol Ther. 2015 Mar;147:63-79. doi: 10.1016/j.pharmthera.2014.11.004. Epub 2014 Nov 6. Review.

PMID:
25444756
10.

CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model.

Domanska UM, Boer JC, Timmer-Bosscha H, van Vugt MA, Hoving HD, Kliphuis NM, Rosati S, van der Poel HG, de Jong IJ, de Vries EG, Walenkamp AM.

Clin Exp Metastasis. 2014 Oct;31(7):829-39. doi: 10.1007/s10585-014-9673-2. Epub 2014 Aug 26.

PMID:
25154297
11.

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.

Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SB, Lub-de Hooge MN, Kosterink JG, de Vries EG, Schröder CP.

Eur J Cancer. 2014 Sep;50(14):2508-16. doi: 10.1016/j.ejca.2014.06.008. Epub 2014 Jul 12.

PMID:
25027745
12.

HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

Kol A, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG, Schröder CP.

Pharmacol Ther. 2014 Jul;143(1):1-11. doi: 10.1016/j.pharmthera.2014.01.005. Epub 2014 Feb 7. Review.

PMID:
24513440
13.

Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.

Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S.

Expert Rev Mol Med. 2013 Sep 30;15:e12. doi: 10.1017/erm.2013.13. Review.

PMID:
24074238
14.

89Zr-bevacizumab PET imaging in primary breast cancer.

Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EG, Schröder CP.

J Nucl Med. 2013 Jul;54(7):1014-8. doi: 10.2967/jnumed.112.117218. Epub 2013 May 7.

15.

Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.

Oude Munnink TH, Tamas KR, Lub-de Hooge MN, Vedelaar SR, Timmer-Bosscha H, Walenkamp AM, Weidner KM, Herting F, Tessier J, de Vries EG.

J Nucl Med. 2013 Jun;54(6):929-35. doi: 10.2967/jnumed.112.112086. Epub 2013 Apr 26.

16.

Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schröder CP, de Vries EG.

Cancer Res. 2013 Jun 1;73(11):3347-55. doi: 10.1158/0008-5472.CAN-12-3518. Epub 2013 Apr 11.

17.

Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus.

Boer JC, Domanska UM, Timmer-Bosscha H, Boer IG, de Haas CJ, Joseph JV, Kruyt FA, de Vries EG, den Dunnen WF, van Strijp JA, Walenkamp AM.

Br J Cancer. 2013 Feb 19;108(3):587-96. doi: 10.1038/bjc.2012.603. Epub 2013 Jan 15.

18.

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.

van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK.

Clin Cancer Res. 2012 Nov 15;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. Epub 2012 Sep 26.

19.

Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN.

Mol Pharm. 2012 Nov 5;9(11):2995-3002. doi: 10.1021/mp3002182. Epub 2012 Oct 11.

PMID:
23003202
20.

CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.

Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, De Vries EG, de Jong IJ, Walenkamp AM.

Neoplasia. 2012 Aug;14(8):709-18.

21.

A review on CXCR4/CXCL12 axis in oncology: no place to hide.

Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM.

Eur J Cancer. 2013 Jan;49(1):219-30. doi: 10.1016/j.ejca.2012.05.005. Epub 2012 Jun 9. Review.

PMID:
22683307
22.

Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance.

van der Bilt AR, van der Zee AG, de Vries EG, de Jong S, Timmer-Bosscha H, ten Hoor KA, den Dunnen WF, Hollema H, Reyners AK.

Curr Pharm Des. 2012;18(25):3784-92. Review.

PMID:
22591424
23.

Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging.

Arjaans M, Oude Munnink TH, Timmer-Bosscha H, Reiss M, Walenkamp AM, Lub-de Hooge MN, de Vries EG, Schröder CP.

Pharmacol Ther. 2012 Aug;135(2):123-32. doi: 10.1016/j.pharmthera.2012.05.001. Epub 2012 May 12. Review.

PMID:
22587883
24.

Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.

van der Bilt AR, de Vries EG, de Jong S, Timmer-Bosscha H, van der Zee AG, Reyners AK.

Crit Rev Oncol Hematol. 2012 Nov;84(2):224-42. doi: 10.1016/j.critrevonc.2012.03.006. Epub 2012 Apr 21. Review.

PMID:
22525643
25.

PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.

Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, Schröder CP, Hesselink JW, Vedelaar SR, Walenkamp AM, Reiss M, Gregory RC, Lub-de Hooge MN, de Vries EG.

J Nucl Med. 2011 Dec;52(12):2001-8. doi: 10.2967/jnumed.111.092809. Epub 2011 Nov 9.

26.

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S.

Cell Death Dis. 2011 Apr 21;2:e148. doi: 10.1038/cddis.2011.33.

27.

Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S.

J Clin Invest. 2010 Oct;120(10):3594-605. doi: 10.1172/JCI41939. Epub 2010 Sep 1.

28.

The chemokine network, a newly discovered target in high grade gliomas.

Domanska UM, Kruizinga RC, den Dunnen WF, Timmer-Bosscha H, de Vries EG, Walenkamp AM.

Crit Rev Oncol Hematol. 2011 Aug;79(2):154-63. doi: 10.1016/j.critrevonc.2010.07.006. Epub 2010 Aug 14. Review.

PMID:
20709564
29.

89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, Lub-de Hooge MN, Schröder CP, de Vries EG.

J Nucl Med. 2010 May;51(5):761-7. doi: 10.2967/jnumed.109.071043. Epub 2010 Apr 15.

30.

(89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.

Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H, Schröder CP, Jong JR, Dongen GA, Jensen MR, Quadt C, Hooge MN, Vries EG.

Eur J Cancer. 2010 Feb;46(3):678-84. doi: 10.1016/j.ejca.2009.12.009. Epub 2009 Dec 24.

PMID:
20036116
31.

Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.

Walenkamp AM, Boer IG, Bestebroer J, Rozeveld D, Timmer-Bosscha H, Hemrika W, van Strijp JA, de Haas CJ.

Neoplasia. 2009 Apr;11(4):333-44.

32.

Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells.

van der Deen M, Homan S, Timmer-Bosscha H, Scheper RJ, Timens W, Postma DS, de Vries EG.

Int J Chron Obstruct Pulmon Dis. 2008;3(3):469-75.

33.

Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.

Neels OC, Koopmans KP, Jager PL, Vercauteren L, van Waarde A, Doorduin J, Timmer-Bosscha H, Brouwers AH, de Vries EG, Dierckx RA, Kema IP, Elsinga PH.

Cancer Res. 2008 Sep 1;68(17):7183-90. doi: 10.1158/0008-5472.CAN-08-0095.

34.

Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells.

van der Deen M, de Vries EG, Visserman H, Zandbergen W, Postma DS, Timens W, Timmer-Bosscha H.

J Biochem Mol Toxicol. 2007;21(5):243-51.

PMID:
17912704
35.

Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice.

van der Deen M, Timens W, Timmer-Bosscha H, van der Strate BW, Scheper RJ, Postma DS, de Vries EG, Kerstjens HA.

Respir Res. 2007 Jul 7;8:49.

36.

ATP-binding cassette (ABC) transporters in normal and pathological lung.

van der Deen M, de Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS.

Respir Res. 2005 Jun 20;6:59. Review.

37.

Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.

Boonstra R, Timmer-Bosscha H, van Echten-Arends J, van der Kolk DM, van den Berg A, de Jong B, Tew KD, Poppema S, de Vries EG.

Br J Cancer. 2004 Jun 14;90(12):2411-7.

38.

An in vitro model for purging of tumour cells from ovarian tissue.

Schröder CP, Timmer-Bosscha H, Wijchman JG, de Leij LF, Hollema H, Heineman MJ, de Vries EG.

Hum Reprod. 2004 May;19(5):1069-75. Epub 2004 Apr 7.

PMID:
15070872
39.

Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.

van Gorkom BA, Timmer-Bosscha H, de Jong S, van der Kolk DM, Kleibeuker JH, de Vries EG.

Br J Cancer. 2002 May 6;86(9):1494-500.

40.

Uptake mechanisms of L-3-[125I]iodo-alpha-methyl-tyrosine in a human small-cell lung cancer cell line: comparison with L-1.

Jager PL, de Vries EG, Piers DA, Timmer-Bosscha H.

Nucl Med Commun. 2001 Jan;22(1):87-96.

PMID:
11233558
41.

Effect of specific or random c-DNA priming on sensitivity of tyrosinase nested RT-PCR: potential clinical relevance.

Calogero A, Hospers GA, Timmer-Bosscha H, Koops HS, Mulder NH.

Anticancer Res. 2000 Sep- Oct;20(5B):3545-8.

PMID:
11131660
42.

Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes.

Calogero A, Timmer-Bosscha H, Schraffordt Koops H, Tiebosch AT, Mulder NH, Hospers GA.

Br J Cancer. 2000 Jul;83(2):184-7.

43.

Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity.

van Der Kolk DM, Vellenga E, van Der Veen AY, Noordhoek L, Timmer-Bosscha H, Ossenkoppele GJ, Raymakers RA, Müller M, van Den Berg E, de Vries EG.

Blood. 2000 Jun 1;95(11):3514-9.

44.

Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis.

Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, Sluiter WJ, van Buuren AH, Mulder NH, de Vries EG.

Clin Cancer Res. 1999 Jun;5(6):1363-8.

45.

Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53.

Sleijfer S, Le TK, de Jong S, Timmer-Bosscha H, Withoff S, Mulder NH.

J Immunother. 1999 Jan;22(1):48-53.

PMID:
9924699
46.

Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2.

Sleijfer S, Asschert JG, Timmer-Bosscha H, Mulder NH.

Int J Cancer. 1998 Jul 3;77(1):101-6.

48.

Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines.

Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Müller M, Groen HJ, Smit EF, de Vries EG.

Int J Cancer. 1997 Nov 4;73(3):362-6.

49.

A new in vitro assay for quantitation of chemotherapy-induced mucositis.

Wymenga AN, van der Graaf WT, Spijkervet FL, Timens W, Timmer-Bosscha H, Sluiter WJ, de Vries EG, Mulder NH.

Br J Cancer. 1997;76(8):1062-6.

50.

Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.

Sark MW, Timmer-Bosscha H, Meijer C, Uges DR, Sluiter WJ, Peters WH, Mulder NH, de Vries EG.

Br J Cancer. 1995 Apr;71(4):684-90.

Supplemental Content

Loading ...
Support Center